GILEAD SCIENCES, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $13.5b $4.6b $5.5b $5.4b $123.0m $6.2b $4.6b $5.7b $480.0m $8.5b
Net Income (Loss) Attributable to Noncontrolling Interest ($13.0m) $16.0m $5.0m ($22.0m) ($34.0m) ($24.0m) ($26.0m) ($52.0m) $0 $0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $13.5b $4.6b $5.5b $5.4b $89.0m $6.2b $4.6b $5.6b $480.0m $8.5b
Amortization $981.0m $1.1b $1.2b $1.1b $1.2b $1.7b $1.8b $2.3b $2.4b $2.4b
Amortization expense $981.0m $1.1b $1.2b $1.1b $1.2b $1.7b $1.8b $2.3b $2.4b $2.4b
Amortization of Intangible Assets $1.8b $2.3b $2.4b $2.4b
Depreciation $177.0m $233.0m $226.0m $255.0m $288.0m $329.0m $323.0m $354.0m $381.0m $370.0m
Depreciation expense $177.0m $233.0m $226.0m $255.0m $288.0m $329.0m $323.0m $354.0m $381.0m $370.0m
Deferred Income Tax Expense (Benefit) ($1.6b) ($962.0m) ($1.8b) $160.0m
Deferred income taxes ($119.0m) ($82.0m) $289.0m ($2.1b) ($214.0m) ($116.0m) ($1.6b) ($962.0m) ($1.8b) $160.0m
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $432.0m $0 $820.0m $800.0m $0 $0 $2.7b $50.0m $4.2b $590.0m
In-process research and development impairments $432.0m $0 $820.0m $800.0m $0 $0 $2.7b $50.0m $4.2b $590.0m
Share-based Payment Arrangement, Expense $380.0m $649.0m $845.0m $636.0m $1.1b $635.0m $645.0m $796.0m $969.0m $894.0m
Share-based Payment Arrangement, Noncash Expense $380.0m $638.0m $845.0m $636.0m $643.0m $635.0m $637.0m $766.0m $835.0m $894.0m
Income Tax Expense (Benefit) $3.6b $8.9b $2.3b ($204.0m) $1.6b $2.1b $1.2b $1.2b $211.0m $1.3b
Interest Expense Nonoperating $977.0m $1.0b
Operating Lease, Expense $162.0m $171.0m $156.0m $162.0m $165.0m $163.0m $169.0m
Other Nonoperating Income (Expense) ($2.0m) ($1.0m)
Changes in operating assets and liabilities:
Additional Financial Items
Accounts payable $47.0m ($430.0m) ($39.0m) ($61.0m) $80.0m ($118.0m) $226.0m ($347.0m) $290.0m ($132.0m)
Accounts receivable, net $1.2b $754.0m $480.0m ($218.0m) ($1.2b) $313.0m ($406.0m) $157.0m $139.0m ($367.0m)
Accrued and other liabilities $425.0m ($818.0m) ($514.0m) ($389.0m) $640.0m $689.0m ($775.0m) $458.0m $108.0m $6.0m
Acquired in-process research and development expenses $0 $4.3b $5.9b $177.0m $944.0m $1.2b $4.7b $1.0b
Acquisitions, including in-process research and development, net of cash acquired $0 ($10.4b) $0 $0 ($25.7b) ($1.4b) ($1.8b) ($1.2b) ($4.8b) ($1.1b)
Equity Securities, FV-NI, Gain (Loss) $0 ($115.0m) ($1.2b) $1.7b $610.0m $657.0m $167.0m ($274.0m) $451.0m
Equity Securities, FV-NI, Unrealized Gain (Loss) $0 ($115.0m) ($1.2b) $1.7b $610.0m $657.0m $167.0m $274.0m $404.0m
Fair Value, Option, Changes in Fair Value, Gain (Loss) ($128.0m)
Goodwill $1.2b $4.2b $4.1b $4.1b $8.1b $8.3b $8.3b $8.3b $8.3b $8.3b
Income tax assets and liabilities, net ($361.0m) ($364.0m) ($1.8b) ($732.0m) ($2.1b)
Increase (Decrease) in Accounts Payable $47.0m ($430.0m) ($39.0m) ($61.0m) $80.0m ($118.0m) $226.0m ($347.0m) $290.0m ($132.0m)
Increase (Decrease) in Accounts Receivable ($1.2b) ($754.0m) ($480.0m) $218.0m $1.2b ($313.0m) $406.0m ($157.0m) ($139.0m) $367.0m
Increase (Decrease) in Inventories $488.0m $253.0m $310.0m $95.0m $195.0m ($11.0m) $310.0m $842.0m $426.0m $1.0b
Inventories ($488.0m) ($253.0m) ($310.0m) ($95.0m) ($195.0m) $11.0m ($310.0m) ($842.0m) ($426.0m) ($1.0b)
Inventory Write-down $572.0m $649.0m $228.0m
Net (gain) loss from equity securities $0 ($115.0m) ($1.2b) $1.7b $610.0m $657.0m $167.0m $274.0m ($451.0m)
Nonoperating Income (Expense) $428.0m $523.0m $676.0m $1.9b ($1.4b) ($639.0m) ($581.0m) $198.0m $6.0m $798.0m
Other, net $162.0m $304.0m $56.0m $184.0m $250.0m $1.2b $780.0m $826.0m $353.0m $480.0m
Prepaid expenses and other ($520.0m) $358.0m $903.0m ($307.0m) ($214.0m) ($42.0m) $70.0m $39.0m ($259.0m) ($311.0m)
Purchases of equity securities ($357.0m) $0 ($346.0m) ($1.8b) ($455.0m) ($380.0m) ($172.0m) ($442.0m) ($492.0m) ($133.0m)
Purchases of marketable debt securities ($23.3b) ($10.2b) ($30.5b) ($20.3b) ($3.5b) ($1.8b) ($1.9b) ($244.0m) ($3.9b)
Stock-based compensation expense $380.0m $638.0m $845.0m $636.0m $643.0m $635.0m $637.0m $766.0m $835.0m $894.0m
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax ($8.0m) ($28.0m)
Net Cash Provided by (Used in) Operating Activities $16.7b $11.9b $8.4b $9.1b $8.2b $11.4b $9.1b $8.0b $10.8b $10.0b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $748.0m $590.0m $924.0m $825.0m $650.0m $579.0m $728.0m $585.0m $523.0m $563.0m
Payments to Acquire Businesses, Net of Cash Acquired $10.4b $0 $0 $25.7b $1.4b $1.8b $1.2b $4.8b $1.1b
Other investing activities, net $0 ($190.0m) ($384.0m) ($171.0m) ($163.0m) ($1.0m) ($1.0m) $58.0m $2.0m
Payments for (Proceeds from) Other Investing Activities $384.0m $171.0m $163.0m $1.0m $1.0m ($58.0m) ($2.0m)
Net Cash Provided by (Used in) Investing Activities ($12.0b) ($16.1b) $14.4b ($7.8b) ($14.6b) ($3.1b) ($2.5b) ($2.3b) ($3.4b) ($4.8b)
Cash flows from financing activities:
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale $1.7b $7.8b $24.3b $22.4b $9.5b $2.2b $1.6b $1.3b $327.0m $55.0m
Proceeds from debt financing, net of issuance costs $5.3b $9.0b $0 $0 $8.2b $0 $0 $2.0b $3.5b $0
Proceeds from maturities of marketable debt securities $1.7b $7.8b $24.3b $22.4b $9.5b $2.2b $1.6b $1.3b $327.0m $55.0m
Proceeds from sales of marketable debt securities $10.4b $1.5b $7.5b $23.2b $730.0m $412.0m $510.0m $2.3b $854.0m
Repayments of Long-term Debt $4.8b
Repayments of debt and other obligations ($2.0b) ($1.8b) ($6.2b) ($2.8b) ($2.5b) ($4.8b) ($1.5b) ($2.2b) ($2.0b) ($1.8b)
Proceeds from Issuance of Common Stock $208.0m $234.0m $289.0m $209.0m $256.0m $169.0m $309.0m $232.0m $422.0m $408.0m
Proceeds from issuances of common stock $208.0m $234.0m $289.0m $209.0m $256.0m $169.0m $309.0m $232.0m $422.0m $408.0m
Payments for Repurchase of Common Stock $11.0b $954.0m $2.9b $1.7b $1.6b $546.0m $1.4b $1.0b $1.1b $1.9b
Repurchases of common stock under repurchase programs ($11.0b) ($954.0m) ($2.9b) ($1.7b) ($1.6b) ($546.0m) ($1.4b) ($1.0b) ($1.1b) ($1.9b)
Proceeds from (Payments to) Noncontrolling Interests ($90.0m)
Dividends paid $2.5b $2.7b $3.0b $3.2b $3.4b $3.6b $3.7b $3.8b $3.9b $4.0b
Payments of dividends ($2k) ($3k) ($3k) ($3k) ($3k) ($4k) ($4k) ($4k) ($4k) ($4k)
Other financing activities, net ($276.0m) ($330.0m) ($486.0m) ($122.0m) ($138.0m) ($145.0m) ($173.0m) ($279.0m) ($281.0m) ($440.0m)
Proceeds from (Payments for) Other Financing Activities ($330.0m) ($486.0m) ($122.0m) ($138.0m) ($145.0m) ($173.0m) ($279.0m) ($281.0m) ($440.0m)
Net Cash Provided by (Used in) Financing Activities ($9.3b) $3.4b ($12.3b) ($7.6b) $770.0m ($8.9b) ($6.5b) ($5.1b) ($3.4b) ($7.7b)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.0m ($85.0m) ($2.0m) $43.0m ($35.0m) ($63.0m) $57.0m ($40.0m) $92.0m
Effect of exchange rate changes on cash and cash equivalents $41.0m $137.0m ($85.0m) ($2.0m) $43.0m ($35.0m) ($63.0m) $57.0m ($40.0m) $92.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $41.0m $137.0m ($85.0m) ($6.3b) ($5.6b) ($659.0m) $74.0m $673.0m $3.9b ($2.4b)
Cash and cash equivalents at beginning of period $12.9b $8.2b $7.6b $11.6b $6.0b $5.3b $5.4b $6.1b $10.0b $7.6b
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.6b $6.0b $5.3b $5.4b $6.1b $10.0b $7.6b
Net change in cash and cash equivalents ($4.6b) ($641.0m) $10.4b ($6.3b) ($5.6b) ($659.0m) $74.0m $673.0m $3.9b ($2.4b)
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $885.0m $1.0b $1.1b $982.0m $951.0m $979.0m $907.0m $891.0m $951.0m $1.0b
Income Taxes Paid, Net $3.2b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.